Studie från Stockholms universitet visar att små mesoporösa kiseldioxidpartiklar blockerar matenzymer och leder till minskning av metaboliska riskfaktorer och blodsockernivåer.
How swallowing extremely small porous silica particles can prevent type 2-diabetes and treat obesity
Major new Swedish study shows small mesoporous silica particles block food enzymes reducing metabolic risk factors and blood sugar levels
Stockholm, May 4, 2019: A multifaceted, scientific study in the peer-reviewed journal Advanced Healthcare Materials showing that a radical new approach using mesoporous silica particles (MSPs) can be used to prevent type 2-diabetes and treat obesity. By blocking food enzyme activity, MSPs reduce energy intake from food and lower blood sugar and other metabolic risk factors. The MSPs are administered orally in solution and passed harmlessly from the body in stools.
The study report comprising a combination of clinical, ex vivo, in vitro and in vivo data:
1) confirms previously reported reductions in glycated hemoglobin (HbA1c) and LDL cholesterol in man in response to MSP ingestion,
2) demonstrates sequestration of pancreatic amylase and lipase in a MSP pore-size dependent manner
3) describes in ex vivo experiments in conditions mimicking intestinal conditions and in vivo experiments in mice, enzyme activities dropped upon exposure to the engineered MSP.
Taken together, the results are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSPs resulting in an enzyme-blocking effect.
The head of the research team behind the study, Professor Tore Bengtsson at the Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University comments:
“To get a deeper understanding of the conditions under which MSPs can trap enzymes of interest, we designed a range of experiments including studies in obese individuals, ex vivo, in vitro and in vivo experiments in mice. The results fully support our original concept of using MSPs as “molecular sieves” to prevent type 2-diabetes and treat obesity.”
Title and full text pdf no password
link to the scientific publication:
Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans, Advanced Healthcare Materials, 2020, https://onlinelibrary.wiley.com/doi/full/10.1002/adhm.202000057
Engineered mesoporous silica particles (MSP) are thermally and chemically stable porous materials composed of pure silica and have attracted attention for their potential biomedical applications. Oral intake of engineered MSP is shown to reduce body weight and adipose tissue in mice. Here, clinical data from a first‐in‐humans study in ten healthy individuals with obesity are reported, demonstrating a reduction in glycated hemoglobin (HbA1c) and low‐density lipoprotein cholesterol, which are well‐established metabolic and cardiovascular risk factors. In vitro investigations demonstrate sequestration of pancreatic α‐amylase and lipase in an MSP pore‐size dependent manner. Subsequent ex vivo experiments in conditions mimicking intestinal conditions and in vivo experiments in mice show a decrease in enzyme activity upon exposure to the engineered MSP, presumably by the same mechanism. Therefore, it is suggested that tailored MSP act by lowering the digestive enzyme availability in the small intestine, resulting in decreased digestion of macronutrient and leading to reduced caloric uptake. This novel MSP based mechanism‐of‐action, combined with its excellent safety in man, makes it a promising future agent for prevention and treatment of metabolic diseases.
www red DiabetologNytt